Selective HDAC6 Inhibitor for the treatment of Alzheimer's and related diseases
- 總結
- Ronald Breslow, Ph.D.
- 技術優勢
- Compounds target HDAC6 with 100-fold selectivity over HDAC1.Specific and selective inhibition of HDAC6 offers a therapy for the treatment of Alzheimer's and other neurological diseases while potentially minimizing off-target toxicities caused by pan-HDAC inhibitors. Patent information:Patent Pending (WO/2011/46855)Tech Ventures Reference: IR M10-078
- 技術應用
- Treatment of Alzheimer's disease through specific HDAC6 inhibition.Potentially useful for other central nervous system diseases such as Parkinson's and Huntington's.
- 詳細技術說明
- Ronald Breslow, Ph.D.
- *Abstract
-
None
- *Inquiry
- Beth KaudererColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- M10-078
- *Principal Investigation
-
- *Publications
- P.A. Marks, R. Breslow. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, Vol. 25, Jan. 2007, pp. 84-90.
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
